Relative Value

The Relative Value of one VY4 stock under the Base Case scenario is 1.916 EUR. Compared to the current market price of 1.423 EUR, SNDL Inc is Undervalued by 26%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VY4 Relative Value
Base Case
1.916 EUR
Undervaluation 26%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
74
vs Industry
79
Median 3Y
0.7
Median 5Y
0.9
Industry
2.7
Forward
0.6
vs History
vs Industry
Median 3Y
-4.9
Median 5Y
-6
Industry
21.6
Forward
-27.5
vs History
30
vs Industry
30
Median 3Y
8.7
Median 5Y
-9.8
Industry
16.9
vs History
23
vs Industry
Median 3Y
-6.9
Median 5Y
-7.7
Industry
22.9
vs History
60
vs Industry
75
Median 3Y
0.5
Median 5Y
0.6
Industry
2.3
vs History
79
vs Industry
86
Median 3Y
0.6
Median 5Y
0.8
Industry
3
Forward
0.5
vs History
90
vs Industry
72
Median 3Y
2.3
Median 5Y
3.2
Industry
5.6
vs History
36
vs Industry
12
Median 3Y
13.4
Median 5Y
-13.7
Industry
13.4
Forward
7.2
vs History
vs Industry
Median 3Y
-13
Median 5Y
-13.8
Industry
16.7
Forward
-67.1
vs History
30
vs Industry
39
Median 3Y
6.7
Median 5Y
-5.9
Industry
16.1
vs History
30
vs Industry
29
Median 3Y
8.1
Median 5Y
-5.8
Industry
18.9
vs History
61
vs Industry
78
Median 3Y
0.5
Median 5Y
0.5
Industry
2

Multiples Across Competitors

VY4 Competitors Multiples
SNDL Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
SNDL Inc
F:VY4
366.3m EUR 0.6 -6.4 10.5 -40.9
US
Eli Lilly and Co
NYSE:LLY
1T USD 16.9 54.6 36.7 39.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
491.8B USD 5.3 19.6 16 20.8
CH
Roche Holding AG
SIX:ROG
271.4B CHF 4.4 28.8 12.2 14.3
UK
AstraZeneca PLC
LSE:AZN
220.4B GBP 5.1 31.4 108.9 159.4
US
Merck & Co Inc
NYSE:MRK
274.9B USD 4.3 14.4 10.2 12.1
CH
Novartis AG
SIX:NOVN
218.8B CHF 4.9 19 12 15.5
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.4 16.3 11.3 13.2
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
144.9B USD 2.3 14.7 7.5 10.2
P/E Multiple
Earnings Growth PEG
CA
SNDL Inc
F:VY4
Average P/E: 24.9
Negative Multiple: -6.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.6
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.6
29%
0.7
CH
Roche Holding AG
SIX:ROG
28.8
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.4
37%
0.8
US
Merck & Co Inc
NYSE:MRK
14.4
15%
1
CH
Novartis AG
SIX:NOVN
19
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
16.3
3%
5.4
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.7
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CA
SNDL Inc
F:VY4
Average EV/EBITDA: 400.9
10.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.7
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16
9%
1.8
CH
Roche Holding AG
SIX:ROG
12.2
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.9
10%
10.9
US
Merck & Co Inc
NYSE:MRK
10.2
6%
1.7
CH
Novartis AG
SIX:NOVN
12
6%
2
DK
Novo Nordisk A/S
CSE:NOVO B
11.3
1%
11.3
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CA
SNDL Inc
F:VY4
Average EV/EBIT: 1 883.6
Negative Multiple: -40.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.3
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.8
15%
1.4
CH
Roche Holding AG
SIX:ROG
14.3
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.4
23%
6.9
US
Merck & Co Inc
NYSE:MRK
12.1
8%
1.5
CH
Novartis AG
SIX:NOVN
15.5
12%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
13.2
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5